Market Overview:
The global end-stage renal disease (ESRD) drugs market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of ESRD, rising geriatric population, and technological advancements in ESRD drugs. Based on type, the calcium succinate segment is projected to lead the global end-stage renal disease (ESRD) drugs market during the forecast period. This can be attributed to its high efficiency and low side effects as compared to other types of dialysis medications. Based on application, hospitals are expected to dominate the global end-stage renal disease (ESRD) drugs market during the forecast period owing to increasing number of patients with ESRD requiring dialysis treatment in hospitals setting across all regions.
 Drugs Industry Outlook.svg)
Product Definition:
End-stage renal disease (ESRD) is a stage of kidney failure in which the kidneys can no longer remove waste and excess fluid from the body. As a result, these substances build up to toxic levels and can cause serious health problems. End-stage renal disease is also called kidney failure, chronic renal failure, or end-stage renal disease.
Use of end-stage renal disease drugs may be necessary to prevent or treat health problems associated with this condition. These drugs include medications that help cleanse the blood (dialysis) and those that replace essential nutrients lost due to poor kidney function (renal replacement therapy).
Calcium Succinate:
Calcium succinate is a calcium salt, specifically of the succinic acid. It has been used as an oral drug for the treatment of ESRD patients and works by increasing urinary excretion through the kidney. The product is commercially available in both solid (calcium succinate) and liquid (calcium succinate) forms.
The global Calcium Succinate, it's usage.
Mk-3866:
Mk-3866 is a novel oral drug that is developed by the pharmaceutical company named as Pfizer, Inc. It works by increasing the amount of fluid in the kidney, which helps to improve the function of kidneys and reduce protein loss from them.
Application Insights:
The hospital application segment dominated the global end-stage renal disease (ESRD) drugs market in 2017, accounting for a share of over 60.0% in that year. The growing prevalence of chronic kidney diseases and rising number of patients undergoing dialysis at hospitals are some factors responsible for this large share. According to data published by the National Chronic Kidney Disease Fact Sheet, 2016 Edition, chronic kidney diseases are expected to affect more than 30 million people across the globe by 2030; currently around 25 million people suffer from ESRD worldwide.
Clinic applications accounted for a smaller share as compared to hospital and ICU applications due to high costs associated with them.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable government initiatives, and increasing healthcare expenditure are some factors driving the regional market. For instance, in September 2016, Pfizer Inc., along with kidney patients and their families through its Patient-Centered Outcomes Research (PCOR) study developed a patient-reported outcome measure for ESRD care that can be used across all settings to improve patient outcomes.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels coupled with improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in awareness about chronic kidney diseases among patients is also expected to drive demand for end-stage renal disease drugs over the forecast period. In addition, growing R&D activities by major companies for development of novel therapies will further fuel growth during the forecast period (2017 To 2030).
Growth Factors:
- Increasing incidence of ESRD due to rising prevalence of diabetes and hypertension
- Growing demand for renal replacement therapies (RRTs)
- Technological advancements in RRTs
- Rising geriatric population
- Increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
End-Stage Renal Disease (ESRD) Drugs Market Research Report
By Type
Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others
By Application
Hospital, Clinic, ICU, Others
By Companies
CTI BioPharma Corp, Merck & Co Inc, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd, CTI BioPharma Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global End-Stage Renal Disease (ESRD) Drugs Market Report Segments:
The global End-Stage Renal Disease (ESRD) Drugs market is segmented on the basis of:
Types
Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, ICU, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CTI BioPharma Corp
- Merck & Co Inc
- Novartis AG
- Prolong Pharmaceuticals LLC
- VESSL Therapeutics Ltd
- CTI BioPharma Corp
 Drugs Market Overview.svg)
Highlights of The End-Stage Renal Disease (ESRD) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Calcium Succinate
- Mk-3866
- Pacritinib
- Sanguinate
- Tesidolumab
- Others
- By Application:
- Hospital
- Clinic
- ICU
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the End-Stage Renal Disease (ESRD) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ESRD drugs are medications that are used to treat kidney failure. These drugs help to improve the patient's quality of life by helping them stay as comfortable as possible while their kidneys continue to function at a reduced level.
Some of the major companies in the end-stage renal disease (esrd) drugs market are CTI BioPharma Corp, Merck & Co Inc, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd, CTI BioPharma Corp.
The end-stage renal disease (esrd) drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 End-Stage Renal Disease (ESRD) Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 End-Stage Renal Disease (ESRD) Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 End-Stage Renal Disease (ESRD) Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the End-Stage Renal Disease (ESRD) Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global End-Stage Renal Disease (ESRD) Drugs Market Size & Forecast, 2020-2028
4.5.1 End-Stage Renal Disease (ESRD) Drugs Market Size and Y-o-Y Growth
4.5.2 End-Stage Renal Disease (ESRD) Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Calcium Succinate
5.2.2 Mk-3866
5.2.3 Pacritinib
5.2.4 Sanguinate
5.2.5 Tesidolumab
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 ICU
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global End-Stage Renal Disease (ESRD) Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 End-Stage Renal Disease (ESRD) Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Calcium Succinate
9.6.2 Mk-3866
9.6.3 Pacritinib
9.6.4 Sanguinate
9.6.5 Tesidolumab
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 ICU
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Calcium Succinate
10.6.2 Mk-3866
10.6.3 Pacritinib
10.6.4 Sanguinate
10.6.5 Tesidolumab
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 ICU
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Calcium Succinate
11.6.2 Mk-3866
11.6.3 Pacritinib
11.6.4 Sanguinate
11.6.5 Tesidolumab
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 ICU
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Calcium Succinate
12.6.2 Mk-3866
12.6.3 Pacritinib
12.6.4 Sanguinate
12.6.5 Tesidolumab
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 ICU
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Calcium Succinate
13.6.2 Mk-3866
13.6.3 Pacritinib
13.6.4 Sanguinate
13.6.5 Tesidolumab
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 ICU
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 End-Stage Renal Disease (ESRD) Drugs Market: Competitive Dashboard
14.2 Global End-Stage Renal Disease (ESRD) Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CTI BioPharma Corp
14.3.2 Merck & Co Inc
14.3.3 Novartis AG
14.3.4 Prolong Pharmaceuticals LLC
14.3.5 VESSL Therapeutics Ltd
14.3.6 CTI BioPharma Corp
